

In The Claims

Please cancel all claims and add the following new claims.

83. A method for treating a B cell mediated malignancy in a patient, said method comprising:

administering to said patient a composition comprising two chimeric proteins; wherein

- (1) the first chimeric protein comprises at least a portion of a V_H region and at least a portion of an immunoglobulin constant region,
 - (2) the second chimeric protein comprises at least a portion of a V_L region and at least a portion of an immunoglobulin constant region,
 - (3) wherein said V_H and said V_L region are isolated from a malignant B cell clone from said patient having said B cell mediated malignancy; and
 - (4) wherein said chimeric proteins are produced in insect cells by a baculovirus expression vector wherein
 - (a) the gene encoding said first chimeric protein is operatively linked to an AcNPV p10 promoter and a honey bee melittin secretory signal sequence, or is operatively linked to an AcNPV polyhedrin promoter and a human placental alkaline phosphatase secretory signal sequence; and
 - (b) the gene encoding said second chimeric protein is operatively linked to an AcNPV p10 promoter and a honey bee melittin secretory signal sequence, or is operatively linked to an AcNPV polyhedrin promoter and a human placental alkaline phosphatase secretory signal sequence;
- and
- wherein said first and said second chimeric proteins are not operatively linked to the same promoter.

027579.0302598

84. The method of claim 83 wherein said V_H or V_L region is an entire variable region.
85. The method of claim 83 wherein said second chimeric protein comprises an immunoglobulin constant region comprising a human kappa or lambda constant region.
86. The method of claim 83 wherein said first chimeric protein comprises an immunoglobulin constant region selected from the group consisting of a human $IgG_{\gamma 1}$ constant region, a human $IgG_{\gamma 2}$ constant region, a human $IgG_{\gamma 3}$ constant region, a human $IgG_{\gamma 4}$ constant region, a human IgA_1 constant region, a human IgA_2 constant region, a human IgM constant region, a human IgD constant region, and a human IgE constant region.
87. The method of claim 86 wherein said first chimeric protein comprises an immunoglobulin constant region comprising a human $IgG_{\gamma 1}$ constant region.
88. The method of claim 83 wherein said chimeric proteins are conjugated to a carrier protein.
89. The method of claim 88 wherein said carrier protein is a keyhole-limpet hemocyanin (KLH).
90. The method of claim 83 wherein said composition is further co-administered with a cytokine or chemokine.
91. The method of claim 90 wherein said cytokine is granulocyte-macrophage-colony stimulating factor (GM-CSF).
92. The method of claim 83 wherein said first and second chimeric proteins comprise a protein comprising said V_H region and a human $IgG_{\gamma 1}$ constant region and a protein comprising said V_L region and a human kappa or lambda chain constant region.
93. The method of claim 83 wherein said insect cells are *Trichoplusia ni* or *Spodoptera frugiperda* (Sf9) cells.

94. The method of claim 83 wherein said chimeric proteins are analyzed for expression by ELISA.

95. The method of claim 83 wherein said chimeric proteins are isolated using a protein selected from the group consisting of protein A, protein G, protein L and other proteins being able to bind to an immunoglobulin binding domain.

96. The method of claim 83 wherein said other protein able to bind an immunoglobulin binding domain is an anti-immunoglobulin antibody.

97. The method of claim 83 wherein said B cell mediated malignancy is a B cell lymphoma.

98. The method of claim 97 wherein said B cell lymphoma is refractory low grade lymphoma or follicular B cell lymphoma.

99. The method of claim 83 wherein the gene encoding a chimeric protein comprising a V_L region and an immunoglobulin constant region is controlled by said polyhedrin promoter in said baculovirus expression vector, and the gene encoding a chimeric protein comprising a V_H region and an immunoglobulin constant region is controlled by said p10 promoter in said baculovirus expression vector.

100. The method of claim 83 wherein the gene encoding a chimeric protein comprising a V_L region and an immunoglobulin constant region is controlled by said polyhedrin promoter in said baculovirus expression vector.

101. The method of claim 83 wherein the gene encoding a chimeric protein comprising a V_H region and an immunoglobulin constant region is controlled by said p10 promoter in said baculovirus expression vector.

102. The method of claim 83 wherein the gene encoding a chimeric protein comprising a V_L region and an immunoglobulin constant region is operatively linked to said human placental alkaline phosphatase secretory signal sequence in said baculovirus expression vector.

103. The method of claim 83 wherein the gene encoding a chimeric protein comprising a V_H region and an immunoglobulin constant region is operatively linked to said honey bee melittin secretory signal sequence in said baculovirus expression vector.